Jayaraman, Swaathi
Wu, Xinyan
Kalari, Krishna R.
Tang, Xiaojia
Kuffel, Mary J.
Bruinsma, Elizabeth S. http://orcid.org/0000-0002-7938-438X
Jalali, Shahrzad
Peterson, Kevin L.
Correia, Cristina
Kudgus, Rachel A.
Kaufmann, Scott H. http://orcid.org/0000-0002-4900-7145
Renuse, Santosh
Ingle, James N. http://orcid.org/0000-0003-1257-7731
Reid, Joel M.
Ames, Matthew M.
Fields, Alan P.
Schellenberg, Matthew J. http://orcid.org/0000-0001-7036-5943
Hawse, John R. http://orcid.org/0000-0003-3406-470X
Pandey, Akhilesh http://orcid.org/0000-0001-9943-6127
Goetz, Matthew P. http://orcid.org/0000-0002-4383-270X
Article History
Received: 10 January 2023
Accepted: 1 December 2023
First Online: 19 December 2023
Competing interests
: M.P.G. and J.R.H. report being inventors on a patent application entitled “Degrading PKCb1 to Treat Cancer”. M.P.G. is the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. and reports personal fees for CME activities from Research to Practice, Clinical Education Alliance, Medscape, and MJH Life Sciences; personal fees serving as a panelist for a panel discussion from Total Health Conferencing and personal fees for serving as a moderator for Curio Science; consulting fees to Mayo Clinic from ARC Therapeutics, AstraZeneca, Biotheranostics, Blueprint Medicines, Lilly, Rna Diagnostics, Sanofi Genzyme, Seattle Genetics and Engage Health Media; and grant funding to Mayo Clinic from Lilly, Pfizer, Sermonix, Loxo, AstraZeneca and ATOSSA Therapeutics. S.H.K. reports grant funding to Mayo Clinic from Eli Lilly and Takeda. The other authors declare no competing interests.